By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Dialysis - Peritoneal Dialysis. According to news reporting out of Patras, Greece, by NewsRx editors, research stated, “The impact of icodextrin (ico) on peritoneal dialysis (PD) extension and patient survival is well established. Predominantly, ico-based solutions were prescribed in high-transporter PD patients.”
Our news journalists obtained a quote from the research, “Advantages of the ico-based solutions include increased biocompatibility, avoidance of glucotoxicity, enhanced ultrafiltration failure (UF), sodium removal rates, better metabolic and blood pressure control. Bimodal solutions and twice daily exchanges of ico-based solutions are two newly introduced strategies to avoid glucose exposure and/or enhance UF in PD patients with UF failure. In addition, a simplified schedule of PD using a single nocturnal exchange of ico in patients with refractory congestive heart failure may represent an alternative option to manage fluid removal and azotaemia.”
According to the news editors, the research concluded: “The use of a simplified schedule of PD with only two ico exchanges or a single ico exchange is a challenging approach for end-stage renal disease patients with preserved residual function who desire to initiate PD.”
For more information on this research see: Icodextrin and peritoneal dialysis: advantages and new applications. International Urology and Nephrology , 2018;50(3):495-500. International Urology and Nephrology can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. (Springer - www.springer.com; International Urology and Nephrology - http://www.springerlink.com/content/0301-1623/)
Our news journalists report that additional information may be obtained by contacting P. Dousdampanis, Hemodialysis Unit Kyanous Stavros Patras, Patras 26225, Greece. Additional authors for this research include C.G. Musso and K. Trigka.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s11255-017-1647-2. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
CITATION: (2018-04-13), Data on Peritoneal Dialysis Discussed by P. Dousdampanis and Colleagues (Icodextrin and peritoneal dialysis: advantages and new applications), Health & Medicine Week, 2424, ISSN: 1532-4605, BUTTER® ID: 015477453
From the newsletter Health & Medicine Week.
https://www.newsrx.com/Butter/#!Search:a=15477453
This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.
We have been in business for more than 20 years and our full contact information is available on our main corporate website.
We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.